{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:01:06Z","timestamp":1777334466592,"version":"3.51.4"},"reference-count":55,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by venous and arterial thrombosis and obstetric complications, driven by antiphospholipid antibodies (APLAs). This review synthesizes the latest advancements and current understanding, diagnosis, and treatment of APS. APLAs, including lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-\u03b22-glycoprotein I (a\u03b22-GPI), interfere with coagulation and endothelial function, as well as with placental health. APS can be primary or secondary; it is often associated with systemic autoimmune diseases like lupus. The pathogenesis of APS remains only partially understood. APLAs promote thrombosis through endothelial damage, platelet activation, and inflammatory signaling pathways. Laboratory diagnosis relies on persistent positivity for APLAs and LAC through tests like ELISA and clotting assays, following a three-step confirmation process. New integrated test systems have been introduced to improve standardization. Classification criteria have evolved, with the 2023 EULAR-ACR criteria providing a weighted, domain-based scoring system, enhancing diagnostic precision. Catastrophic APS (CAPS) is a severe, rare manifestation of APS, characterized by multi-organ failure due to rapid, widespread microthrombosis and systemic inflammation, which requires urgent anticoagulation. Seronegative APS is proposed for patients with clinical features of APS but negative standard antibody tests, possibly due to non-criteria antibodies or transient immunosuppression. Treatment primarily involves long-term anticoagulation with vitamin K antagonists; direct oral anticoagulants are generally not recommended. APS diagnosis and management remain complex due to clinical heterogeneity and laboratory challenges. Continued refinement of diagnostic tools and criteria is essential for improving outcomes in this life-threatening condition.<\/jats:p>","DOI":"10.3390\/metabo15080500","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T09:53:02Z","timestamp":1753696382000},"page":"500","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antiphospholipid Syndrome\u2014Diagnostic and Methodologic Approach"],"prefix":"10.3390","volume":"15","author":[{"given":"Agata","family":"Sta\u0144czewska","sequence":"first","affiliation":[{"name":"L. Rydygier Provincial Integrated Hospital in Torun, ul. \u015awi\u0119tego J\u00f3zefa 53-59, 87-100 Torun, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-3882","authenticated-orcid":false,"given":"Karolina","family":"Szewczyk-Golec","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Biology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-5604","authenticated-orcid":false,"given":"Iga","family":"Ho\u0142y\u0144ska-Iwan","sequence":"additional","affiliation":[{"name":"Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000000932","article-title":"Antiphospholipid syndrome (APS) management: A 2023 update and practical algorithm-based approach","volume":"35","author":"Ambati","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/asheducation-2015.1.53","article-title":"The antiphospholipid syndrome: Still an enigma","volume":"2015","author":"Chaturvedi","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_3","first-page":"552","article-title":"The Diagnostic Value of New Additional Antiphospholipid Antibodies in Antiphospholipid Syndrome","volume":"51","author":"Khogeer","year":"2021","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yun, Z., Duan, L., Liu, X., Cai, Q., and Li, C. (2023). An update on the biologics for the treatment of antiphospholipid syndrome. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1145145"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100041","DOI":"10.1016\/j.bvth.2024.100041","article-title":"Understanding the structure of \u03b22-glycoprotein I: New insights and future paths for antiphospholipid syndrome","volume":"2","author":"Kumar","year":"2025","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"P\u00e9rez, D., Stojanovich, L., Naranjo, L., Stanisavljevic, N., Bogdanovic, G., Serrao, M., and Serrano, A. (2018). Presence of Immune Complexes of IgG\/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02644"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2016.155184","article-title":"Obstetric antiphospholipid syndrome: Early variations of angiogenic factors are associated with adverse outcomes","volume":"102","author":"Mercier","year":"2017","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of Antiphospholipid Syndrome in the General Population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cei.13647","article-title":"Follicular helper and follicular regulatory T cell subset imbalance is associated with higher activated B cells and abnormal autoantibody production in primary anti-phospholipid syndrome patients","volume":"206","author":"Long","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tektonidou, M.G. (2018). Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01181"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2015.10.003","article-title":"A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus","volume":"15","author":"Ho","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cei.13385","article-title":"Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases","volume":"199","author":"Gulli","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11926-014-0415-x","article-title":"New tests to detect antiphospholipid antibodies: Antiprothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies","volume":"16","author":"Sciascia","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0961203312441983","article-title":"Antiphosphatidylserine\/prothrombin antibodies in primary antiphospholipid syndrome","volume":"21","author":"Hoxha","year":"2012","journal-title":"Lupus"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Naranjo, L., Stojanovich, L., Djokovic, A., Andreoli, L., Tincani, A., Ma\u015bli\u0144ska, M., Sciascia, S., Infantino, M., Garcinu\u00f1o, S., and Kostyra-Grabczak, K. (2022). Circulating immune-complexes of IgG\/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.957201"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Buchholz, I., McDonnell, T., Nestler, P., Tharad, S., Kulke, M., Radziszewska, A., Ripoll, V.M., Schmidt, F., Hammer, E., and Toca-Herrera, J.L. (2021). Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84021-2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ajcp\/98.4.449","article-title":"Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion","volume":"98","author":"Lopez","year":"1992","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.33963\/KP.15090","article-title":"Antiphospholipid syndrome and the risk of myocardial infarction: Current evidence and uncertaines","volume":"78","author":"Kappelmayer","year":"2020","journal-title":"Kardiol. Pol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-beta2glycoprotein I antibody detection assays","volume":"16","author":"Chayoua","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ijlh.14268","article-title":"Noncriteria antiphospholipid antibodies in antiphospholipid syndrome","volume":"46","author":"Devreese","year":"2024","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/0961203312437439","article-title":"Antibodies against domain I of \u03b22-glycoprotein I: The one and only?","volume":"21","author":"Pelkmans","year":"2012","journal-title":"Lupus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100610","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS","volume":"39","author":"McDonnell","year":"2020","journal-title":"Blood Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"Agar","year":"2010","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rauch, J., Salem, D., Subang, R., Kuwana, M., and Levine, J. (2018). \u03b22-Glycoprotein I-Reactive T Cells in Autoimmune Disease. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02836"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1719720","DOI":"10.1155\/2016\/1719720","article-title":"The Role of TLR4 on B Cell Activation and Anti- \u03b22GPI Antibody Production in the Antiphospholipid Syndrome","volume":"2016","author":"Cheng","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109843","DOI":"10.1016\/j.intimp.2023.109843","article-title":"Neutrophil extracellular trap: A key player in the pathogenesis of autoimmune diseases","volume":"116","author":"Sadeghi","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/cei.12573","article-title":"Laboratory evaluation of anti-phospholipid syndrome: A preliminary prospective study of phosphatidylserine\/prothrombin antibodies in an at-risk patient cohort","volume":"180","author":"Heikal","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clim.2018.03.001","article-title":"Treatment of antiphospholipid syndrome beyond anticoagulation","volume":"206","author":"Dobrowolski","year":"2019","journal-title":"Clin Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2005.07.1288","article-title":"Preliminary prospective study of the endocrinology of conception cycles and early pregnancy in women with antiphospholipid syndrome treated with low molecular weight heparin","volume":"85","author":"Prakash","year":"2006","journal-title":"Fertil. Steril."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7150\/ijms.7.15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2010","journal-title":"Int. J. Med. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Marinho, A., Delgado Alves, J., Fortuna, J., Faria, R., Almeida, I., Alves, G., Correia, J.A., Campar, A., Brand\u00e3o, M., and Crespo, J. (2023). Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj\u00f6gren\u2019s syndrome: Evidence and practice-based guidance. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1117699"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.berh.2017.09.008","article-title":"Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome","volume":"31","year":"2017","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.berh.2016.07.004","article-title":"Catastrophic antiphospholipid syndrome: The current management approach","volume":"30","author":"Espinosa","year":"2016","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-009-0073-6","article-title":"Update on the Diagnosis, Treatment, and Prognosis of the Catastrophic Antiphospholipid Syndrome","volume":"12","author":"Cervera","year":"2010","journal-title":"Curr Rheumatol Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1749-6632.2009.04642.x","article-title":"Human leukocyte antigen-DRB1 and -DQB1 genotyping in lupus patients with and without antiphospholipid syndrome","volume":"1173","author":"Kapitany","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2024074","DOI":"10.4084\/MJHID.2024.074","article-title":"The Performance of 2023 American College of Rheumatology (ACR)\/European Alliance of Associations for Rheumatology (EULAR) Antiphospholipid Syndrome Classification Criteria in a Real-World Rheumatology Department","volume":"16","author":"Usta","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J. Thromb. Haemosis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/17843286.2025.2519714","article-title":"Lupus anticoagulant testing in Belgian laboratories: A comparison with the 2020 International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH-SSC) guidelines","volume":"80","author":"Vanhove","year":"2025","journal-title":"Acta Clin. Belg."},{"key":"ref_44","first-page":"81","article-title":"Diagnosis of the prolonged activated partial thromboplastin time (aPTT)","volume":"1","author":"Chojnowski","year":"2010","journal-title":"Hematologia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1515\/cclm-2021-0692","article-title":"Anti-phosphatidyl-serine\/prothrombin antibodies (aPS\/PT) in isolated lupus anticoagulant (LA): Is their presence linked to dual test positivity?","volume":"59","author":"Tonello","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/acr.24520","article-title":"Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I\/II Report: Generation and Reduction of Candidate Criteria","volume":"73","author":"Barbhaiya","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_48","first-page":"103","article-title":"New classification criteria for antiphospholipid syndrome\u20142023","volume":"16","year":"2023","journal-title":"J. Trans. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/acr.22388","article-title":"Thrombotic risk assessment in systemic lupus erythematosus: Validation of the global antiphospholipid syndrome score in a prospective cohort","volume":"66","author":"Sciascia","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_50","first-page":"164","article-title":"Establishment of ELISA-comparable moderate and high thresholds for anticardiolipin and anti-\u03b22 glycoprotein I chemiluminescent immunoassays according to the 2023 ACR\/EULAR APS classification criteria and evaluation of their diagnostic performance","volume":"63","author":"Rotar","year":"2024","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_52","first-page":"CD012169","article-title":"Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome","volume":"10","author":"Bala","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3324\/haematol.2022.281586","article-title":"Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome","volume":"107","author":"Giarretta","year":"2022","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure","volume":"19","author":"Pengo","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: A randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/8\/500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:16:59Z","timestamp":1760033819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/15\/8\/500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["metabo15080500"],"URL":"https:\/\/doi.org\/10.3390\/metabo15080500","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]}}}